Novo and Viking present new MASH data, but analysts remain confident in...
Novo Nordisk and Viking Therapeutics took to the annual Liver Meeting to make the case for their experimental MASH drugs as they chase Madrigal Pharmaceuticals' first-ever approved treatment for the...
View ArticleWhen generative AI meets the FDA: First digital health adcomm kicks off...
How to regulate generative AI was the central topic of the inaugural two-day meeting of the FDA’s new digital health advisory committee that began on Wednesday. FDA Commissioner Rob Califf opened the...
View ArticleFDA updates label of 33-year-old cancer drug with new dose and warning
The FDA on Wednesday updated the label for Sandoz's decades-old leukemia drug fludarabine phosphate, as part of a wider initiative to revamp the labels for cancer drugs approved long ago. Fludarabine...
View ArticleVenrock adds $500M to healthcare investing strategy after outlining 10th fund...
Venrock has added half a billion dollars to its healthcare investing strategy, the firm confirmed to Endpoints News on Wednesday. It comes on top of its $650 million 10th fund — which goes toward
View ArticleNewAmsterdam aces Phase 3 trial, but investors are skeptical
NewAmsterdam Pharma’s lead cardio program obicetrapib passed another Phase 3 trial, demonstrating its ability to lower “bad cholesterol” in combination with a drug called ezetimibe. The TANDEM study...
View ArticleKyowa Kirin buys into Kura leukemia treatment rights for $330M+
Japanese drugmaker Kyowa Kirin is acquiring most of the commercial rights for Kura Oncology’s targeted leukemia treatment, paying $330 million upfront and almost $1.2 billion in possible milestones....
View ArticleAmgen names geneticist and biotech founder to CSO post
Amgen is joining the chorus of large pharmas naming new science leaders. The company said Wednesday that Stanford physician-scientist Howard Chang will be its new chief scientific officer and senior...
View ArticleNovartis buys Kate Therapeutics in $1.1B deal, eyes more bolt-on M&A
Novartis is buying gene therapy and neuroscience biotech Kate Therapeutics in a deal worth $1.1 billion in upfront and milestone payments, the Swiss pharma confirmed to Endpoints News on Thursday. And...
View ArticleAizen debuts with AI-driven 'mirror peptide' platform
Aizen Therapeutics has left stealth with $13 million in seed funding and a mission to advance “mirror peptide” drug candidates, with an initial focus on solid tumors and neuroscience. The San...
View ArticleFDA vaccine chief Peter Marks pledges to stay as long as he's welcome
LONDON — The FDA's top leader of vaccines and biologics said Thursday he is not planning to leave his role in light of the incoming Trump administration and the potential for Robert F. Kennedy Jr ...
View ArticleCidara's $100M PIPE; Pyxis Oncology's stock falls on Phase 1 data
Plus, news about argenx, Forte Biosciences, Verrica, Pep2Tango Therapeutics, Eli Lilly, Laekna, Lineage Cell Therapeutics and OneCell Diagnostics: Cidara Therapeutics nabs $105M: The immunotherapy...
View ArticleSamsung Bio's new $668M client; Sanofi expands a factory in France
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Samsung Biologics has secured a number of ...
View ArticleTrump and RFK Jr. want to ban pharma ads. History isn't on their side
As the healthcare priorities of President-elect Donald Trump and his HHS pick Robert F. Kennedy Jr. take shape, one idea gaining steam is a ban on direct-to-consumer pharmaceutical advertising. Both...
View ArticleAt Jefferies, all that manufacturers want to talk about is GLP-1s
LONDON — Thousands of delegates flooded into the narrow corridors of the Waldorf Hilton this week to attend the Jefferies London Healthcare Conference. It was so busy that at one point, security had to...
View ArticleJazz wins approval for bispecific in biliary tract cancer
Jazz Pharmaceuticals earned an FDA approval on Wednesday for zanidatamab, the HER2-targeted bispecific antibody it picked up from Zymeworks for $50 million upfront. The drug, to be marketed as Ziihera,...
View ArticleAstraZeneca culls Phase 2 opioid use disorder drug
AstraZeneca ended a Phase 2 trial of an experimental opioid use disorder treatment, the UK pharma confirmed to Endpoints News. The termination was due to “discontinuation of the AZD4041 clinical...
View ArticleFDA adcomm raises risk questions on AstraZeneca’s Andexxa
Members of an FDA advisory committee were not asked to vote Thursday on AstraZeneca’s anticoagulant reversal drug Andexxa, but they did raise several safety and efficacy concerns. Last year,...
View ArticleWith yearslong reorganization behind it, Novartis increases its sales guidance
Novartis’ reorganization is paying off, CEO Vas Narasimhan told investors at an event Thursday in London. The company raised its sales guidance through 2028 and now expects to grow sales at a 6% annual...
View ArticlePatient dies in Neurogene's Rett syndrome study
A female Rett syndrome patient died Wednesday after receiving Neurogene's gene therapy in a clinical trial, the company disclosed in a new regulatory filing, after saying earlier this week that she ...
View ArticleEnveda raises $130M for drugs in I&I, obesity and other areas
Biotech startup Enveda has raised a $130 million Series C, the Colorado company said Thursday morning. Founded and led by early Recursion employee Viswa Colluru, the startup will use the funds ...
View Article